12个月，他们投向医疗30亿

Core Insights - The article highlights the resurgence of the innovative drug sector in China, marking 2025 as a pivotal year for medical innovation, with significant investment activity and market performance [2][6] - The investment strategy of Qiming Venture Partners, focusing on innovative drugs and medical devices, has proven successful, with a notable increase in IPOs and market valuations in the sector [3][7] Investment Trends - In 2025, Qiming Venture Partners invested in over 30 projects in the medical innovation field, contributing more than 30 billion RMB, with some investments made in late 2024 [3][6] - The company has been particularly active in supporting innovative surgical robotics, exemplified by its early investment in Cornerstone Robotics, which has raised over 3 billion RMB [3][4] Market Dynamics - The medical sector experienced a downturn in 2021, leading to cautious investment behavior among many firms; however, Qiming maintained close industry engagement during this period [6][7] - By mid-2024, Qiming's strategy of investing in undervalued Chinese innovations began to yield positive results, coinciding with a broader market recovery [7][8] Global Recognition - In 2025, approximately 40% of new drug projects licensed in by global pharmaceutical companies originated from Chinese biotech firms, a significant increase from 0% in 2019 [9][10] - The article emphasizes the growing global influence of Chinese medical innovations, with successful business development (BD) transactions indicating the capability of Chinese firms to collaborate with leading global pharmaceutical companies [10][11] Future Outlook - The article suggests that the next phase of medical investment will focus on building a sustainable ecosystem for biopharmaceuticals, with an emphasis on global market participation [8][12] - Qiming Venture Partners aims to assist its portfolio companies in navigating global markets, having facilitated numerous BD transactions totaling 19.7 billion USD by October 2025 [11][12]